A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
Bristol-Myers Squibb
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained. * Participants must have an unresectable/metastatic carcinoma. Exclusion Criteria * Participants must not have Leptomeningeal metastases. * Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment. * Participants must…
Interventions
- DrugBMS-986463
Specified dose on specified days
Locations (17)
- USC/Norris Comprehensive Cancer CenterLos Angeles, California
- Valkyrie Clinical TrialsLos Angeles, California
- John Theurer Cancer Center at Hackensack University Medical CenterHackensack, New Jersey
- Local Institution - 0045Columbus, Ohio
- Local Institution - 0046Dallas, Texas
- Local Institution - 0049Houston, Texas